BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Trade War'. (Return)

MarketWatch MarketPulseJun 24, 2019
UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal
Bristol-Myers Squibb Co. shares fell 4% in premarket trade Monday, after the company said a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals. The company said the Phase 3 study called CheckMate -459 evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma, or HCC, failed to meet its primary endpoint of overall survival, or OS. "While CheckMate -459 did not reach its pre-specified primary endpoint, the results showed a clear trend towards improvement in OS for patients treated with Opdivo compared to sorafenib, a current standard of care," the company said in a statement. The full study results will be presented at a coming medical meeting, said the statement. HCC is the fastest rising cause of cancer-related death in the U.S. Separately, Bristol-Myers said it is planning to sell Otezla, a treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene Corp. . "The proceeds of the OTEZLA sale will allow Bristol-Myers Squibb to accelerate its post-closing deleveraging plans," the company said. The companies are expecting to close the deal at year-end or in early 2020. Bristol-Myer shares are down 5.2% in 2019 through Friday, while the S&P 500 has gained 17.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal (MarketWatch MarketPulse)

MarketWatch MarketPulseJun 24, 2019
Stocks open slightly higher as investors eye Trump-Xi meeting later this week
Stocks opened with small gains Monday as investors looked ahead to a meeting later this week between President Donald Trump and Chinese leader Xi Jinping. Analysts attributed a positive tone to hopes the meeting at the Group of 20 summit in Japan will produce a cease-fire in the U.S.-China trade war. The Dow Jones Industrial Average rose 56.47 points, or 0.2%, to 26,775.60, while the S&P 500 was up 3.69 points, or 0.1%, to 2,954.15. The Nasdaq Composite was 14.48 points higher at 8,046.18. Shares of Caesars Entertainment jumped nearly 15% after the casino operator agreed to a buyout valued at about $8.6 billion buyout by Eldorado Resorts Inc.. Eldorado shares were off 7.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
TrumpTrump-Xi meet Meeting Fed China
DealCaesars Eldorado Resorts Entertainment UPDATE
Stocksoil US-Iran G20 Asian higher
stockoil US-Iran higher G20 Asian
China5G Huawei trade should Trump
H2Ocuts exposure bonds liquidity illiquid
Buydeal Stocks Eldorado Caesars Resorts
MarketStocks stock higher GLOBAL oil
higherstocks trade focus markets Tech
Caesarsdeal Eldorado Resorts Entertainment Billion

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2019 CEOExpress Company LLC